GlaxoSmithKline Pharmaceuticals Limited (IN:GLAXO)
:GLAXO
Want to see IN:GLAXO full AI Analyst Report?
GLAXO Stock Chart & Stats
₹2483.35
-₹2.55(-0.12%)
At close: 4:00 PM EST
₹2483.35
-₹2.55(-0.12%)
Day’s Range― - ―
52-Week Range₹2,136.05 - ₹3,500.00
Previous CloseN/A
Volume25.42K
Average Volume (3M)1.83K
Market Cap
₹368.34B
Enterprise Value₹360.84B
Total Cash (Recent Filing)₹20.61B
Total Debt (Recent Filing)₹357.10M
Price to Earnings (P/E)35.6
Beta0.69
Next Earnings
Jul 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.16%
Share Statistics
EPS (TTM)56.39
Shares Outstanding169,406,040
10 Day Avg. Volume1,472
30 Day Avg. Volume1,831
Financial Highlights & Ratios
PEG Ratio3.20
Price to Book (P/B)17.06
Price to Sales (P/S)10.12
P/FCF Ratio39.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)69.53
Revenue Forecast (FY)₹42.07B
Bulls Say, Bears Say
Bulls Say
Strong ProfitabilityHigh 2026 net (~27%) and EBIT (~33%) margins indicate durable pricing power and operating leverage in its branded formulation model. Sustained margins increase free cash generation, support reinvestment in R&D/brands and provide a structural buffer versus lower‑margin competitors.
Conservative Balance SheetExtremely low leverage preserves financial flexibility, reduces refinancing/default risk, and enables opportunistic investment or M&A without diluting operations. A conservative capital structure is a durable advantage through regulatory or demand cycles.
High Cash Quality And ROEFCF closely tracking net income and very high ROE reflect high-quality earnings and efficient capital use. Reliable cash conversion supports dividends, capex and product investment, reducing reliance on external funding for sustainable growth.
Bears Say
Profitability VolatilityLarge swings in margins — including a >50% outlier in 2022 — suggest one-offs or timing effects materially influence reported profits. This volatility weakens earnings predictability, complicates long-term planning for R&D and commercial investment, and raises forecasting risk.
Cash Conversion VariabilityWide variation in operating cash conversion indicates working-capital swings. Irregular cash inflows can create funding mismatches, force short-term borrowing or delay investments, and make free cash flow less dependable for sustaining growth or payouts.
Modest Revenue GrowthLow single-digit revenue growth implies limited organic top-line momentum, meaning future earnings gains may depend more on margin expansion than volume. Modest sales growth reduces runway for scale benefits and increases vulnerability to competitive share loss.
GlaxoSmithKline Pharmaceuticals Limited News
GLAXO FAQ
What was GlaxoSmithKline Pharmaceuticals Limited’s price range in the past 12 months?
GlaxoSmithKline Pharmaceuticals Limited lowest stock price was ₹2136.05 and its highest was ₹3500.00 in the past 12 months.
What is GlaxoSmithKline Pharmaceuticals Limited’s market cap?
GlaxoSmithKline Pharmaceuticals Limited’s market cap is ₹368.34B.
When is GlaxoSmithKline Pharmaceuticals Limited’s upcoming earnings report date?
GlaxoSmithKline Pharmaceuticals Limited’s upcoming earnings report date is Jul 27, 2026 which is in 45 days.
How were GlaxoSmithKline Pharmaceuticals Limited’s earnings last quarter?
GlaxoSmithKline Pharmaceuticals Limited released its earnings results on May 13, 2026. The company reported ₹16.4 earnings per share for the quarter, beating the consensus estimate of N/A by ₹16.4.
Is GlaxoSmithKline Pharmaceuticals Limited overvalued?
According to Wall Street analysts GlaxoSmithKline Pharmaceuticals Limited’s price is currently Overvalued.
Does GlaxoSmithKline Pharmaceuticals Limited pay dividends?
GlaxoSmithKline Pharmaceuticals Limited pays a Annually dividend of ₹57 which represents an annual dividend yield of 2.16%. See more information on GlaxoSmithKline Pharmaceuticals Limited dividends here
What is GlaxoSmithKline Pharmaceuticals Limited’s EPS estimate?
GlaxoSmithKline Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GlaxoSmithKline Pharmaceuticals Limited have?
GlaxoSmithKline Pharmaceuticals Limited has 169,406,040 shares outstanding.
What happened to GlaxoSmithKline Pharmaceuticals Limited’s price movement after its last earnings report?
GlaxoSmithKline Pharmaceuticals Limited reported an EPS of ₹16.4 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.685%.
Which hedge fund is a major shareholder of GlaxoSmithKline Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:GLAXO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise, engages in the research, development, production, and global distribution of pharmaceutical drugs and vaccines. Its extensive product range encompasses both prescription and over-the-counter medications addressing diverse therapeutic areas such as anti-infectives, respiratory ailments, dermatology, nutritional deficiencies, gastrointestinal issues, and rare conditions. The company additionally provides consumer healthcare solutions. Prominent brands within its portfolio include Augmentin, Calpol, Ceftum, Eltroxin, Neosporin, Betnovate, Infanrix Hexa, Synflorix, and Boostrix, among numerous others. Founded in 1924 and headquartered in Mumbai, India, the company adopted its current name in 2001, having previously operated as SmithKline Beecham Pharmaceuticals India Ltd.
Technical Analysis
Cipla Ltd
―
Dr. Reddy's Laboratories Ltd.
―
Lupin Limited
―
Sun Pharmaceutical Industries Limited
―
Torrent Pharmaceuticals Ltd
―